Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04181138 · ClinicalTrials.gov registry record
Primary Sclerosing Cholangitis in Children
A clinical trial of Liver Diseases and Primary Sclerosing Cholangitis, sponsored by Arbor Research Collaborative for Health.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 12
- Study locations
NCT04181138 is a study of Liver Diseases and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Arbor Research Collaborative for Health. The registered enrollment target is 1,000 participants, below the 61,128-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT04181138, a study of Liver Diseases and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Arbor Research Collaborative for Health.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 12
- Study locations
Study Summary
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: * Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly. * Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning * Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.
Conditions Studied
Study Locations (12)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
California
- Children's Hospital of Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- Ann & Robert H Lurie Children's Hospital - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Ohio
- Cincinnati Children's Hospital Medical - Cincinnati
Texas
- Texas Children's Hospital (Baylor College of Medicine) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2029-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04181138
The ClinicalTrials.gov registry entry for NCT04181138 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,128-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower). The listed sponsor is Arbor Research Collaborative for Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT04181138 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Pennsylvania, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04181138 about?
NCT04181138 is a clinical study titled "Primary Sclerosing Cholangitis in Children". Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC,...
What is the current status of trial NCT04181138?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-12-30. Estimated completion is 2029-05-31.
What conditions does trial NCT04181138 study?
This clinical trial studies the following conditions: Liver Diseases, Primary Sclerosing Cholangitis, Cholangitis, Sclerosing.
Who is sponsoring clinical trial NCT04181138?
This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04181138 being conducted?
This trial has 12 study locations across California, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.